| Alvin F. Wong |
Alvin F. Wong is currently the Chief Scientific Officer at Puma Biotechnology, Inc. He previously worked as the Senior Director-Clinical Development at Proteolix, Inc. from 2007 to 2013. Prior to that, he served as a Clinical Professor at UCSF School of Pharmacy from 1976 to 1996. Dr. Wong holds a graduate degree from The University of California, San Francisco. |
| Jeffrey Ludwig |
Jeffrey Ludwig is currently the Chief Commercial Officer at Puma Biotechnology, Inc. Prior to this, he was the Vice President-Oncology Sales at Amgen, Inc. from 2014 to 2019 and at Astellas Pharma, Inc. from 2019 to 2020. He completed his undergraduate degree at Arizona State University. |
| Alan H. Auerbach |
Alan H. Auerbach is the founder of Puma Biotechnology, Inc. (founded in 2010) and Cougar Biotechnology, Inc. (founded in 2003). At Puma Biotechnology, Inc., he holds the titles of Chairman, President, CEO & Secretary. At Cougar Biotechnology, Inc., he held the title of President, Chief Executive Officer & Director from 2003 to 2009. Mr. Auerbach also held former positions at Innovative Acquisitions Corp., where he was Chairman, President & Chief Executive Officer. He was an Independent Director at Radius Health, Inc. from 2011 to 2017. He was Vice President & Senior Research Analyst at Diagnostic Products Corp. in 2011. He also held the position of Vice President & Senior Research Analyst at Wells Fargo Securities (Old) from 1998 to 2003 and at Seidler Cos., Inc. from 1997 to 1998. In terms of education, Mr. Auerbach completed his undergraduate degree at Boston University and his graduate degree at the University of Southern California. |
| Maximo F. Nougues |
Maximo F. Nougues is currently the Chief Financial & Accounting Officer at Puma Biotechnology, Inc. Prior to this, he worked as the Chief Financial Officer-North America Region at Getinge AB from 2008 to 2018. He also held the position of Chief Financial Officer & Regional VP-Finance at MAQUET Cardiovascular LLC. Nougues graduated from Universidad Del Norte Santo Tomas De Aquino with a graduate degree and earned an MBA from McLaren School of Business. |
| Brian M. Stuglik |
Brian M. Stuglik is the founder of Proventus Health Solutions LLC, which was founded in 2016. He held the title of Member at Proventus Health Solutions LLC. Mr. Stuglik's current jobs include being an Independent Director at Oncopeptides AB since 2018, a Director at Verastem, Inc. since 2017, and an Independent Director at Puma Biotechnology, Inc. since 2020. He is also a Member of the American Society of Clinical Oncology, Inc., the American Association for Cancer Research, and the International Association for the Study of Lung Cancer. Mr. Stuglik's former job was as the Chief Marketing Officer & Vice President at Eli Lilly & Co. from 2009 to 2015. He obtained his undergraduate degree from Purdue University. |
| Allison Dorval |
Allison Dorval is an Independent Director at Puma Biotechnology, Inc., Aerovate Therapeutics, Inc., and Chief Financial Officer at Verve Therapeutics, Inc. She previously worked as a Finance Director at Digitas, Inc., Vice President & Controller at Catalent JNP, Inc., Assistant Controller at iBASIS, Inc., Chief Financial Officer at Arsenal Medical, Inc. and Lyra Therapeutics, Inc., and Chief Financial Officer at Insulet Corp. She also served as a Principal at PricewaterhouseCoopers LLP. Ms. Dorval obtained her undergraduate degree from the University of Vermont. |
| Troy E. Wilson |
Troy E. Wilson is the founder of Avidity Biosciences, Inc. (founded in 2012) and Kura Oncology, Inc. (founded in 2014), where he holds the title of Non-Executive Chairman and Chairman, President, CEO & Chief Financial Officer respectively. He also founded Ambrx, Inc. in 2003, where he served as the Chief Business Officer, and Intellikine LLC in 2007, where he held the positions of President, Chief Executive Officer & Director. Dr. Wilson is also the founder of Wildcat Discovery Technologies, Inc. Dr. Wilson's current job positions include Executive Chairman at Wellspring Biosciences LLC (since 2012), Executive Chairman at Abintus Bio, Inc. (since 2020), Independent Director at Puma Biotechnology, Inc. (since 2013), and Managing Member at Araxes Pharma LLC (since 2012). His former job positions include Chairman, President & Chief Executive Officer at Zeta Acquisition Corp. III, Chief Executive Officer at Takeda Pharmaceuticals U.S.A., Inc., Director at ZP Opco, Inc., Independent Director at Zosano Pharma Corp. (2014-2019), and Vice President-Business Development at Novartis Institute for Functional Genomics, Inc. Dr. Wilson's education includes a graduate degree from New York University and undergraduate and doctorate degrees from the University of California, Berkeley. |
| Adrian M. Senderowicz |
Adrian M. Senderowicz is currently serving as an Independent Director at Puma Biotechnology, Inc., a Non-Executive Director at Oncoinvent AS, and a Director at Step Pharma SAS. He previously worked as a Senior Medical Director at AstraZeneca PLC, Vice President of Global Regulatory Oncology at Sanofi, Head of Prostate Cancer Clinic at National Institutes of Health, Clinical Team Leader at US Food & Drug Administration, Chief Medical Officer & VP of Medical Development at Tokai Pharmaceuticals, Inc., Chief Medical Officer & Senior Vice President at Cerulean Pharma, Inc., Chief Medical Officer & Senior Vice President at Constellation Pharmaceuticals, Inc., Chief Medical Officer & SVP of Regulatory Affairs at Ignyta, Inc., and Chief Medical Officer & Senior Vice President at Daré Bioscience, Inc. He holds a doctorate degree from Universidad de Buenos Aires. |
| Alessandra Cesano |
Alessandra Cesano is currently an Independent Director at Puma Biotechnology, Inc., an Independent Non Executive Director at Summit Therapeutics, Inc., and a Director at Zymeworks, Inc. She is also a Member of the American Society of Clinical Oncology, Inc., the American Association for Cancer Research, the American Society of Hematology, the International Society for Biological Therapy of Cancer, the European Society for Medical Oncology, the European Hematology Association, and the Society For Immunotherapy of Cancer. Previously, she held positions as Vice President at Amgen, Inc., VP & Medical Officer-Oncology Medical Research at Biogen, Inc., Chief Operating & Medical Officer at Nodality, Inc., Principal at The Wistar Institute, Chief Medical Officer at NanoString Technologies, Inc., and Chief Medical Officer at Cleave Therapeutics, Inc. Dr. Cesano holds a doctorate degree from the University of Turin and an undergraduate degree from Istituto Tecnico Economico O. F. Mossotti di Novara. |
| Jay M. Moyes |
Jay M. Moyes is currently the Lead Independent Director at Puma Biotechnology, Inc., an Independent Director at BioCardia, Inc., a Member of the Utah Association of Certified Public Accountants, and the Managing Member of Drayton Investments LLC. Previously, he served as an Independent Non-Executive Director at Osiris Therapeutics, Inc. from 2006 to 2017. He was also the Chief Financial Officer & Director at SINTX Technologies, Inc. from 2012 to 2014, an Independent Director at Integrated Diagnostics, Inc. from 2011 to 2016, and an Independent Director at Predictive Technology Group, Inc. in 2019. Additionally, he held the position of Chief Financial Officer at Myriad Genetics, Inc. from 2005 to 2007, Chief Financial Officer & Vice President-Finance at Genmarks, Inc. from 1991 to 1993, and Chief Financial Officer at CareDx, Inc. from 2008 to 2009. Prior to that, he worked as a Senior Manager at KPMG LLP from 1979 to 1991. He also served as a Trustee at the Utah Life Science Association from 1999 to 2006. Mr. Moyes holds an MBA from the University of Utah and an undergraduate degree from Weber State University. |
| Michael Patrick Miller |
Michael Patrick Miller currently works at Puma Biotechnology, Inc., as Independent Director from 2018, BioXcel Therapeutics, Inc., as Independent Director from 2022, and Zane Beadles Parade Foundation, as Director. Mr. Miller also formerly worked at The Leukemia & Lymphoma Society, Inc., as Director, Allena Pharmaceuticals, Inc., as Director, ALZA Corp., as Vice President from 1997 to 2001, Genentech, Inc., as Vice President-Sales & Marketing from 2006 to 2010, Cellegy Pharmaceuticals, Inc., as Vice President-Commercial Operations, VIVUS, Inc., as Chief Commercial Officer & Senior Vice President from 2010 to 2014, Connetics Corp., as Senior Vice President-Sales & Marketing from 2003 to 2005, and Jazz Pharmaceuticals Plc, as Executive Vice President-Commercial from 2017 to 2020. Mr. Miller received his undergraduate degree and graduate degree from Duke University, Masters Business Admin degree from San Francisco State University, and undergraduate degree from the University of San Francisco. |
